(Reuters) - U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they could sell copycat versions of Novo Nordisk's diabetes drug Ozempic for less than $100 a month.

Vt., renewed his criticism of drugmaker Novo Nordisk on Tuesday, claiming that the CEOs of major generic pharmaceutical companies have told him that they can produce and sell its blockbuster diabetes drug Ozempic for less than $100 a month.

Senator Bernie Sanders (I-Vt.) once again ramped up pressure on weight loss drugmakers, announcing that he received confirmation from CEOs of major generic drugmakers that Novo Nordisk’s (NVO) blockbuster obesity medicine Ozempic can be sold profitably at $100 per month.